跳至主要内容
临床试验/NCT03643900
NCT03643900已完成不适用

Clinical Research on the Prophylactic Efficacy of Pancreatic Duct Stenting Combined With Rectal Indomethacin Drug on Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

First People's Hospital of Hangzhou1 个研究点 分布在 1 个国家目标入组 618 人开始时间: 2018年8月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
618
试验地点
1
主要终点
the incidence of PEP

研究概览

简要总结

With the development of endoscopic technology, ERCP has been widely used in the diagnosis and treatment of pancreatobiliary diseases, and has become the first treatment for most of the biliary and pancreatic diseases. Postoperative ERCP pancreatitis (PEP) is the most common and serious complication after ERCP. The purpose of this study was to explore methods for preventing postoperative pancreatitis.

  1. Participants: Patients with high-risk factors associated with PEP were included in the no-obvious patients who underwent therapeutic ERCP in our hospital from June 2018 to December 2019.
  2. Research methods: Patients were randomly divided into indometacin suppositories, indomethacin suppositories and pancreatic stents.
  3. Statistical methods: SPSS 13.0 statistical software was used. The measurement data was expressed as x± s, and t-test or non-parametric test was used. Chi-square test was used for count data.

详细描述

Patients with high risk factors for PEP who will be examined and diagnosed by ERCP at 2018.06-2019.12 in the First People's Hospital of Hangzhou are randomly divided into two groups.

  1. Record the relevant indicators of each group of patients: 1 before and after surgery 3, 12, 24 h serum amylase changes 2 patients with abdominal pain, abdominal distension, fever, vomiting and abdominal signs of change; 3 hospital days; 4 CT severity index (CT severity Index, CTSI score: Balthazar 5 scores were scored as 0 to 4 points; according to the scope of necrosis was divided into no, <33%, 33% to 50%,> 50%, respectively rated as 0, 2, 4 and 6 points. Addition of the two scores is the CTSI score. 5 According to the diagnostic criteria for postoperative ERCP pancreatitis, PEP will be diagnosed in patients with persistent abdominal pain within 24 hours after ERCP and blood amylase increase by more than 3 times the normal value. Observed 2 groups of post-ERCP pancreatitis, severe pancreatitis and adverse events Incidence.

  2. Analyze and compare the above indicators and observe the effect of the two methods on the reduction of blood amylase level and incidence of pancreatitis. It is clear that rectal administration of preoperative indomethacin suppository has the same protection against PEP as pancreatic stenting effect.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age over 18 years old,gender is not limited; Preoperative blood amylase is normal; PEP risk factors during surgery:difficulty in intubation,needle knife incision,intraoperative intubation into the pancreatic duct more than 3 times,the contrast agent in the pancreatic duct is filled; The research procedure is willing to be followed and the informed consent is signed.

排除标准

  • Myocardial infarction occurred within 3 months; Insufficiency of renal function; Conventional gastrectomy; Preoperative state of shock,such as hypotension(systolic blood pressure less than 90mmHg); Pregnancy and lactation; Allergic to NSAIDs drugs; Partially or completely restricted in the ability to exercise consciousness,without self-determination ability; Are participating in other clinical observation trials or have participated in other clinical trials within 60 days; Cases considered unsuitable by the investigator.

研究组 & 干预措施

indomethacin with stenting group

Experimental

Pancreatic duct stenting and rectal indomethacin 100mg at preoperative 30min in 100 patients

干预措施: pancreatic duct stenting (Device)

indomethacin with stenting group

Experimental

Pancreatic duct stenting and rectal indomethacin 100mg at preoperative 30min in 100 patients

干预措施: rectal indomethacin (Drug)

indomethacin group

Active Comparator

Rectal indomethacin 100mg at preoperative 30min in 100 patients

干预措施: rectal indomethacin (Drug)

结局指标

主要结局

the incidence of PEP

时间窗: 24 hours

the rate of patients with PEP

次要结局

  • the incidence of severe PEP(7 days)
  • CT severity index(72 hours)

研究者

发起方
First People's Hospital of Hangzhou
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jianfeng Yang

chief physician

First People's Hospital of Hangzhou

研究点 (1)

Loading locations...

相似试验